The antimicrobial peptide Defensin cooperates with Tumour Necrosis Factor to drive tumour cell death in Drosophila
Citations Over Time
Abstract
Abstract Antimicrobial peptides (AMPs) are small cationic molecules best known as mediators of the innate defence against microbial infection. While in vitro and ex vivo evidence suggest AMPs’ capacity to kill cancer cells, in vivo demonstration of an anti-tumour role of endogenous AMPs is lacking. Using a Drosophila model of tumourigenesis, we demonstrate a role for the AMP Defensin in the control of tumour progression. Our results reveal that Tumour Necrosis Factor mediates exposure of phosphatidylserine (PS), which makes tumour cells selectively sensitive to the action of Defensin remotely secreted from tracheal and fat tissues. Defensin binds tumour cells in PS-enriched areas, provoking cell death and tumour regression. Altogether, our results provide the first in vivo demonstration for a role of an endogenous AMP as an anti-cancer agent, as well as a mechanism that explains tumour cell sensitivity to the action of AMPs.
Related Papers
- → Cyclic Peptides as Novel Therapeutic Microbicides: Engineering of Human Defensin Mimetics(2017)93 cited
- → Mouse Beta-Defensin-14, an Antimicrobial Ortholog of Human Beta-Defensin-3(2008)53 cited
- → Dysregulation of human beta-defensin-3 expression in the peripheral blood of patients with sepsis(2021)5 cited
- → Differential expression of α‐ and β‐defensins in human peripheral blood(2003)76 cited
- HUMAN DEFENSIN PEPTIDES WITH ANTIMICROBIAL PROPERTIES: AN OVERVIEW(2012)